Premium
P4‐143: OBSERVATIONS ON THE FREQUENCY OF DEPRESSION AND MEDICATIONS IN AN APOE‐ε4 VERSUS NON‐ APOE‐ε4 POPULATION
Author(s) -
Keine Dorothy,
Walker John Q.,
Sabbagh Marwan N.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2547
Subject(s) - depression (economics) , apolipoprotein e , geriatric depression scale , population , medicine , psychiatry , disease , depressive symptoms , cognition , economics , environmental health , macroeconomics
combination therapy early to obtain additional benefit. Neurologists (34%) are more likely than Geriatricians (25%) to utilize higher doses than recommended in product package inserts. For new treatments, cognition, behavior, activities/functionality and disease progression are outcomes of most interest. Both groups think disease modifying treatments (DMT) and new symptomatic treatments (ST) are needed, however, Neurologists (57%) appear to value availability of new ST more than Geriatricians (27%). When DMT is available, 40% of physicians expect to use both ST and DMT in combination, while 27% expect to treat with DMT first and use ST later. More Geriatricians (21%) vs Neurologists (7%) would consider using ST only after the effect of DMT is absent. Conclusions: Geriatricians and Neurologists approach AD treatment initiation and changes in therapy similarly; they differ in patient assessment, willingness to use higher doses, perceived value for new symptomatic treatments, and use of symptomatic treatments in presence of disease modifying treatments.